Your consulting firm has been hired to perform a cost-effectiveness analysis (CEA) for DeviceCos new wi-fi/4G capable Radio Frequency Identity Device (RFID) implantable deep brain stimulator to treat epilepsy. The device has recently been approved by the FDA for adults (over 18 years of age) who have not responded well to other medical treatments.

The new device has the capability to provide a locate function to alert first responders when a person experiences seizures. The device uses a combination of Wi-Fi, GPS and medical technology. The device provides location data and transmits real-time patient medical information.

1 ,Describe how performing the analysis from the patient perspective differs from performing the analysis from the societal perspective in terms of identifying costs. Give examples to support your answer.

2,Describe the type of costing methodology you would recommend be used for the analysis, the type of data it will require and any limitations of the approach.

3,How would the assessment you perform differ if you use a cost-benefit analysis (CBA) instead of a cost-effectiveness analysis (CEA)? Which would you choose (CBA or CEA) and why?